Effects of rosuvastatin combined with clopidogrel bisulfate on blood lipids, cardiac function and inflammatory factor levels in elderly patients with coronary heart disease

Hongyun Gao; Juanjuan Han; Guoping Li; Wenjing Zhang

Effects of rosuvastatin combined with clopidogrel bisulfate on blood lipids, cardiac function and inflammatory factor levels in elderly patients with coronary heart disease

Am J Transl Res. 2022 Feb 15;14(2):1297-1304. eCollection 2022.

Authors

Hongyun Gao¹, Juanjuan Han¹, Guoping Li², Wenjing Zhang¹

Affiliations

¹ Special Inspection Department, Dongying City People's Hospital Dongying, China.
² Department of Cardiology, Dongying City People's Hospital Dongying, China.

PMID: 35273731
PMCID: PMC8902559

Abstract

Objective: To investigate the effects of rosuvastatin combined with clopidogrel bisulfate on blood lipids, cardiac function, and inflammatory factor levels in elderly patients with coronary heart disease (CHD).

Methods: A total of 100 elderly patients with CHD treated in our hospital from January 2018 to January 2020 were retrospectively selected and assigned to the control group (n=50) and the observation group (n=50) according to different types of medications. The control group was treated with clopidogrel bisulfate, while the observation group was treated with clopidogrel bisulfate combined with rosuvastatin. T₁, T₂, T₃, and T₄, which indicated 5, 10, 15, and 20 days after medication respectively, were set up to observe the changes of relevant indexes in the two groups after medication. The changes in blood lipids, cardiac function, and inflammatory factors were compared between the two groups.

Results: The clinical efficacy of the observation group was superior to the control group (P<0.05). No significant differences were determined in the levels of TC and LDL-C at T₁ and T₂ between the two groups (P>0.05); however, the observation group obtained lower TC and LDL-C levels than the control group at T₃ and T₄ (P<0.05). The levels of hs-CRP, TNF-α, BNP and NT-proBNP were not significantly different between the two groups at T₁ and T₂ (P>0.05), and lower levels of hs-CRP, TNF-α, BNP and NT-proBNP were observed in the observation group than in the control group at T₃ and T₄ (P<0.05). The two groups presented no significant differences in the left ventricular ejection fraction (LVEF) level and the Wall Motion Score Index (WMSI) score (P>0.05). After treatment, the observation group scored higher in the LVEF level and lower in the WMSI score than the control group (both P<0.05). The adverse reaction rate of the two groups was similar (P>0.05).

Conclusion: Rosuvastatin combined with clopidogrel bisulfate is effective in the treatment of elderly patients with CHD, which can effectively improve the cardiac function of patients and reduce the levels of blood lipids and inflammatory factors.

Keywords: Rosuvastatin; blood lipids; cardiac function; clopidogrel bisulfate; coronary heart disease; elderly patients; inflammatory factors.